Bovine Herpesvirus Type 1 (BHV-1/IBR)
Antiserum

<table>
<thead>
<tr>
<th>Catalog No.</th>
<th>PAB-IBR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
<td>P150129-005</td>
</tr>
<tr>
<td>Expiration</td>
<td>23 February 2019</td>
</tr>
</tbody>
</table>

Quality Control Method: Indirect FA using BHV-1/IBR 12-well slide (catalog no. SLD-IFA-IBR), and anti-caprine IgG FITC conjugate (catalog no. CJ-F-CAPG-1ML or 10ML).

Specific Reaction: 2-4+ fluorescence at 1/400, no background, with an endpoint equal to or greater than 1/10,000.

Other Comments: NA

QC Manager: Torrey Beeson

QC Release Date: 23 February 2015

Pattern Of Fluorescence: Primarily undifferentiated cytoplasmic with some nuclear fluorescence, especially in rounded cells and degenerating cells in plaques with acellular centers.

FA Cross-Reaction Screening: The Antiserum has been screened by indirect FA and has been found to react with reovirus (REO), trace to 1+ at 1/100, but does not react with bovine adenovirus type 1, 3, and 5 (BAV-1, 3, and 5), bovine coronavirus (BCV), bovine leukemia virus (BLV), bovine parvovirus (BPV), bovine respiratory syncytial virus (BRSV), bluetongue virus (BTV), bovine viral diarrhea virus (BVDV), parainfluenza virus type 3 (PI-3), Rabies Recombinant Nucleoprotein (rNP), vesicular stomatitis virus Indiana and New Jersey strains (VSV).

Technical Data Sheet Version: Version # 1